BRPI0506851A - dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina contendo pelo menos um ácido graxo - Google Patents

dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina contendo pelo menos um ácido graxo

Info

Publication number
BRPI0506851A
BRPI0506851A BRPI0506851-7A BRPI0506851A BRPI0506851A BR PI0506851 A BRPI0506851 A BR PI0506851A BR PI0506851 A BRPI0506851 A BR PI0506851A BR PI0506851 A BRPI0506851 A BR PI0506851A
Authority
BR
Brazil
Prior art keywords
delivering
calcium antagonists
fatty acid
delivery device
transdermal delivery
Prior art date
Application number
BRPI0506851-7A
Other languages
English (en)
Inventor
James Osborne
Meenal Chavan
Original Assignee
Lavipharm Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lavipharm Lab Inc filed Critical Lavipharm Lab Inc
Publication of BRPI0506851A publication Critical patent/BRPI0506851A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

DISPOSITIVO DE DISTRIBUIçãO TRANSDéRMICA PARA DISTRIBUIR ANTAGONISTAS DE CáLCIO DO TIPO DIIDROPIRIDINA CONTENDO PELO MENOS UM áCIDO GRAXO Um dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina através da pele para tratamento de hipertensão. O dispositivo pode compreender uma camada de revestimento protetor e um reservatório de matriz adesiva. O reservatório de matriz adesiva é fixado a um lado da camada de revestimento protetor e pode compreender pelo menos um intensificador de permeação de ácido graxo, bem como os antagonistas de cálcio do tipo diidropiridina.
BRPI0506851-7A 2004-01-14 2005-01-14 dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina contendo pelo menos um ácido graxo BRPI0506851A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53634404P 2004-01-14 2004-01-14
PCT/US2005/001302 WO2005067897A1 (en) 2004-01-14 2005-01-14 Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid

Publications (1)

Publication Number Publication Date
BRPI0506851A true BRPI0506851A (pt) 2007-06-12

Family

ID=34794398

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506851-7A BRPI0506851A (pt) 2004-01-14 2005-01-14 dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina contendo pelo menos um ácido graxo

Country Status (13)

Country Link
US (1) US20050186262A1 (pt)
EP (1) EP1711170B1 (pt)
JP (1) JP2007520480A (pt)
KR (1) KR20060123551A (pt)
CN (1) CN1929827A (pt)
AT (1) ATE437634T1 (pt)
AU (1) AU2005204391A1 (pt)
BR (1) BRPI0506851A (pt)
CA (1) CA2552887A1 (pt)
DE (1) DE602005015679D1 (pt)
ES (1) ES2330653T3 (pt)
IL (1) IL176802A0 (pt)
WO (1) WO2005067897A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
CN102370625A (zh) * 2010-08-20 2012-03-14 江苏联环药业股份有限公司 非洛地平片
EP2583645A1 (en) * 2011-10-21 2013-04-24 Josek Berek Apolet Skin lesion protector
CN114569730B (zh) * 2022-01-25 2024-06-14 鑫稳生物医药科技(嘉善)有限公司 非洛地平促透剂组合、非洛地平经皮给药制剂及经皮递送装置

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US5045553A (en) * 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
LU87068A1 (fr) * 1987-12-09 1989-07-07 Oreal Association a base de derives de pyrimidine et d'antagonistes de calcium en vue d'induire et de stimuler la croissance des cheveux et diminuer leur chute
JP3002493B2 (ja) * 1990-03-12 2000-01-24 積水化学工業株式会社 経皮吸収製剤
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
IL104192A (en) * 1992-02-17 1998-01-04 Siegfried Ag Pharma Pharmaceutical dosage forms having prolonged release rate of zero order of the active ingredient
JPH07145061A (ja) * 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 経皮吸収製剤
US6106856A (en) * 1994-03-09 2000-08-22 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Transdermal delivery of calcium channel blockers, such as nifedipine
GR1002079B (en) * 1994-07-26 1995-12-05 Lavipharm A E System of a special structure and composition for the rapid transdermal administration of oestrogens.
JP4024852B2 (ja) * 1994-11-17 2007-12-19 東レ株式会社 「経皮吸収製剤」
US6133443A (en) * 1996-02-23 2000-10-17 Mercian Corporation Optically active 1,4-dihydropyridine derivatives and process for the preparation thereof
JP3460538B2 (ja) * 1997-10-08 2003-10-27 救急薬品工業株式会社 速溶性フィルム製剤
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US6627663B2 (en) * 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
EP1117404A1 (en) * 1998-10-02 2001-07-25 Sucampo AG Composition for treatment of light-injured retinal degeneration disease
JP2000136128A (ja) * 1998-10-29 2000-05-16 Hisamitsu Pharmaceut Co Inc エストラジオール含有貼付剤
US6772223B1 (en) * 2000-04-10 2004-08-03 International Business Machines Corporation Configurable classification interface for networking devices supporting multiple action packet handling rules
JP4648518B2 (ja) * 2000-06-01 2011-03-09 帝國製薬株式会社 ４−ビフェニル酢酸含有貼付剤
EP1328273B1 (en) * 2000-10-23 2008-07-02 Euro-Celtique S.A. Felodipine transdermal device and methods
US20020126672A1 (en) * 2001-01-10 2002-09-12 Nelson Chow Method and apparatus for a flexible and reconfigurable packet classifier using content addressable memory
US6813690B1 (en) * 2001-06-12 2004-11-02 Network Appliance, Inc. Caching media data using content-sensitive identifiers
US7126907B2 (en) * 2001-08-31 2006-10-24 Tropic Networks Inc. Label switched communication network, a method of conditioning the network and a method of data transmission
JP4792193B2 (ja) * 2002-08-28 2011-10-12 久光製薬株式会社 貼付剤

Also Published As

Publication number Publication date
AU2005204391A1 (en) 2005-07-28
US20050186262A1 (en) 2005-08-25
EP1711170A1 (en) 2006-10-18
ATE437634T1 (de) 2009-08-15
KR20060123551A (ko) 2006-12-01
IL176802A0 (en) 2006-10-31
CN1929827A (zh) 2007-03-14
EP1711170B1 (en) 2009-07-29
JP2007520480A (ja) 2007-07-26
DE602005015679D1 (de) 2009-09-10
ES2330653T3 (es) 2009-12-14
WO2005067897A1 (en) 2005-07-28
CA2552887A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
ES2543977T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
BR0317876A (pt) Composições de liberação de droga tópica estáveis
EA201070123A1 (ru) Устройство доставки в кожу с изолирующим слоем in situ
ECSP077309A (es) Compuestos amido y sus usos como farmaceuticos
WO2007035942A3 (en) Transdermal risperidone delivery system
AR050621A1 (es) Sistema terapeutico transdermal con una capa adherente procedimiento para el siliconado de una capa de respaldo y empleo de la capa de respaldo
PE20060680A1 (es) Compuestos de morfolina sustituida como inhibidores de la recaptacion de norepinefrina
RU2016109449A (ru) Устройства для трансдермальной доставки дексмедетомидина и способы их применения
BRPI0506851A (pt) dispositivo de distribuição transdérmica para distribuir antagonistas de cálcio do tipo diidropiridina contendo pelo menos um ácido graxo
BR0313091A (pt) Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina
ATE389432T1 (de) Vorrichtung zur transdermalen verabreichung von wirkstoffen
BRPI0418373A (pt) composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado
EA201591124A1 (ru) Трансдермальная система доставки
BRPI0307777B8 (pt) emplastro transdérmico
ATE415153T1 (de) Pharmazeutische zusammensetzung zur perkutane absorption unter verwendung von einem metalchlorid, vorzugsweise natriumchlorid, zur vorbeugung von kohäsionsschwäche
DK1355636T3 (da) Transdermalt terapeutisk system til administrering af carboxylgruppeholdige, ikke-steroidale antiflogistika samt en fremgangsmåde til fremstilling deraf
ATE429908T1 (de) Hormonhaltiges transdermales therapeutisches system mit einem wirkstoffreservoir auf der basis von vinylacetat-vinylpyrrolidon-copolymer mit verbesserter kohäsion.
DK1450773T3 (da) Transdermalt terapeutisk system med forbedret langvarig bærekomfort
WO2006058017A3 (en) Transmucosal oral delivery device
RU2009137122A (ru) Устройство для трансдермального введения бисопролола
ATE415154T1 (de) Pharmazeutische zusammensetzung zur perkutane absorption unter verwendung von einem metalchlorid, vorzugsweise natriumchlorid, zur vorbeugung von kohäsionsschwäche
ATE403420T1 (de) Transdermalsystem mit fentanyl
DK1524971T3 (da) Forbedret transdermalt leveringssystem
NZ584190A (en) Once-a-day replacement transdermal administration of fentanyl
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]